Description

BRACANAT 150 MG TAB (1X30)

Indications

BRACANAT 150 MG TAB is primarily indicated for the treatment of specific types of breast cancer, particularly in patients who are carriers of BRCA1 and BRCA2 gene mutations. These mutations significantly increase the risk of developing breast and ovarian cancers. BRACANAT is used as a part of a comprehensive treatment plan that may include surgery, chemotherapy, and radiation therapy. It is also indicated for the treatment of advanced ovarian cancer in patients who have received at least three prior lines of chemotherapy.

Mechanism of Action

The active ingredient in BRACANAT is a PARP (poly ADP-ribose polymerase) inhibitor. PARP is an enzyme involved in DNA repair mechanisms. In cancer cells with BRCA1 or BRCA2 mutations, the DNA repair pathway is already compromised. By inhibiting PARP, BRACANAT prevents the repair of single-strand breaks in DNA, leading to the accumulation of DNA damage and ultimately causing cell death. This mechanism selectively targets cancer cells while sparing normal cells, making it a valuable therapeutic option for patients with BRCA mutations.

Pharmacological Properties

BRACANAT exhibits a high degree of specificity for PARP enzymes, which contributes to its effectiveness in treating cancers associated with BRCA mutations. The pharmacokinetics of BRACANAT indicate that it is rapidly absorbed after oral administration, with peak plasma concentrations occurring within a few hours. The drug is metabolized primarily in the liver and is excreted through both urine and feces. The half-life of BRACANAT allows for once-daily dosing, which enhances patient compliance.

Contraindications

BRACANAT is contraindicated in patients who have a known hypersensitivity to the active ingredient or any of the excipients in the formulation. Additionally, it should not be used in patients with severe hepatic impairment, as this may lead to increased drug exposure and potential toxicity. Pregnant or breastfeeding women should also avoid using BRACANAT due to the potential risk of harm to the fetus or infant.

Side Effects

Like all medications, BRACANAT may cause side effects. Common side effects include nausea, fatigue, vomiting, and anemia. Other potential side effects may involve changes in liver function tests, thrombocytopenia (low platelet count), and diarrhea. Serious adverse effects, although less common, may include myelodysplastic syndromes and acute myeloid leukemia. Patients should be monitored regularly for these side effects, and any significant changes should be reported to a healthcare provider immediately.

Dosage and Administration

The recommended dosage of BRACANAT is 150 mg taken orally once daily. It can be taken with or without food; however, it is advisable to take it at the same time each day to maintain consistent drug levels in the bloodstream. In cases where a dose is missed, patients should take the missed dose as soon as they remember, unless it is close to the time of the next scheduled dose. In such cases, the missed dose should be skipped, and patients should not take two doses at once. Dose adjustments may be necessary based on the patient’s tolerance and the presence of side effects.

Interactions

BRACANAT may interact with other medications, which can affect its efficacy and safety. Notably, strong CYP3A inhibitors can increase the plasma concentration of BRACANAT, leading to an increased risk of side effects. Conversely, strong CYP3A inducers may decrease the effectiveness of BRACANAT by lowering its plasma levels. Patients should inform their healthcare providers of all medications they are taking, including over-the-counter drugs and herbal supplements, to minimize the risk of drug interactions.

Precautions

Before starting treatment with BRACANAT, patients should undergo a thorough assessment to confirm the presence of BRCA mutations. Regular monitoring of blood counts and liver function tests is essential during treatment to detect any potential adverse effects early. Patients should also be advised to maintain adequate hydration and report any signs of infection or unusual bleeding. It is crucial for women of childbearing age to use effective contraception during treatment and for a period after discontinuation, as BRACANAT may cause fetal harm.

Clinical Studies

Clinical studies have demonstrated the efficacy of BRACANAT in patients with BRCA-mutated breast and ovarian cancers. In a pivotal trial, BRACANAT showed a significant improvement in progression-free survival compared to standard chemotherapy in patients with recurrent ovarian cancer. The results indicated that patients receiving BRACANAT experienced longer periods without disease progression, highlighting its role as an effective therapeutic option in this patient population. Ongoing studies continue to evaluate the long-term outcomes and safety profile of BRACANAT in various settings.

Conclusion

BRACANAT 150 MG TAB represents a significant advancement in the treatment of breast and ovarian cancers associated with BRCA mutations. Its unique mechanism of action as a PARP inhibitor allows for targeted therapy, providing hope for patients who have limited treatment options. While it is essential to consider potential side effects and interactions, the benefits of BRACANAT in improving patient outcomes make it a valuable addition to cancer treatment protocols. Ongoing research will further elucidate its role in oncology and may expand its indications in the future.